Baidu
map

Lancet:Rimegepant崩解片治疗偏头痛

2019-07-14 MedSci MedSci原创

研究认为,75mg Rimegepant崩解片可有效缓解急性偏头痛患者症状

Rimegepant是一种小分子降钙素基因相关肽受体拮抗剂,在急性偏头痛治疗中显示出良好的治疗前景。近日研究人员考察了新型口服Rimegepant崩解片在偏头痛急性治疗中的疗效、安全性和耐受性。

18岁以上,偏头痛史至少1年的患者参与本次III期临床研究,随机接受75mg Rimegepant崩解片或安慰剂,主要疗效终点为服药后2小时偏头痛症状消失。

1375名患者参与研究,其中rimegepant组682人,安慰剂组693人参与疗效评估。服药2小时后,rimegepant组21%的患者无疼痛症状,安慰剂组为11%;rimegepant组35%的患者因偏头痛导致的焦虑情绪缓解,安慰剂组为27%。最常见的不良反应是恶心和尿路感染

研究认为,75mg Rimegepant崩解片可有效缓解急性偏头痛患者症状。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1685333, encodeId=ad5b168533391, content=<a href='/topic/show?id=8d9f15481b0' target=_blank style='color:#2F92EE;'>#rimegepant#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15481, encryptionId=8d9f15481b0, topicName=rimegepant)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=badc28130480, createdName=spoonycyy, createdTime=Sun Feb 09 01:17:00 CST 2020, time=2020-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830153, encodeId=fe5e183015360, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Mar 24 22:17:00 CST 2020, time=2020-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427336, encodeId=acd2142e33615, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Tue Jul 16 01:17:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369648, encodeId=952136964833, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/05/12a5266c80310ee47ca553700511f53c.jpg, createdBy=b5512215816, createdName=永远不放弃, createdTime=Sun Jul 14 11:16:31 CST 2019, time=2019-07-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1685333, encodeId=ad5b168533391, content=<a href='/topic/show?id=8d9f15481b0' target=_blank style='color:#2F92EE;'>#rimegepant#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15481, encryptionId=8d9f15481b0, topicName=rimegepant)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=badc28130480, createdName=spoonycyy, createdTime=Sun Feb 09 01:17:00 CST 2020, time=2020-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830153, encodeId=fe5e183015360, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Mar 24 22:17:00 CST 2020, time=2020-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427336, encodeId=acd2142e33615, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Tue Jul 16 01:17:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369648, encodeId=952136964833, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/05/12a5266c80310ee47ca553700511f53c.jpg, createdBy=b5512215816, createdName=永远不放弃, createdTime=Sun Jul 14 11:16:31 CST 2019, time=2019-07-14, status=1, ipAttribution=)]
    2020-03-24 howi
  3. [GetPortalCommentsPageByObjectIdResponse(id=1685333, encodeId=ad5b168533391, content=<a href='/topic/show?id=8d9f15481b0' target=_blank style='color:#2F92EE;'>#rimegepant#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15481, encryptionId=8d9f15481b0, topicName=rimegepant)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=badc28130480, createdName=spoonycyy, createdTime=Sun Feb 09 01:17:00 CST 2020, time=2020-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830153, encodeId=fe5e183015360, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Mar 24 22:17:00 CST 2020, time=2020-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427336, encodeId=acd2142e33615, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Tue Jul 16 01:17:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369648, encodeId=952136964833, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/05/12a5266c80310ee47ca553700511f53c.jpg, createdBy=b5512215816, createdName=永远不放弃, createdTime=Sun Jul 14 11:16:31 CST 2019, time=2019-07-14, status=1, ipAttribution=)]
    2019-07-16 gwc384
  4. [GetPortalCommentsPageByObjectIdResponse(id=1685333, encodeId=ad5b168533391, content=<a href='/topic/show?id=8d9f15481b0' target=_blank style='color:#2F92EE;'>#rimegepant#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15481, encryptionId=8d9f15481b0, topicName=rimegepant)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=badc28130480, createdName=spoonycyy, createdTime=Sun Feb 09 01:17:00 CST 2020, time=2020-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830153, encodeId=fe5e183015360, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Mar 24 22:17:00 CST 2020, time=2020-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427336, encodeId=acd2142e33615, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Tue Jul 16 01:17:00 CST 2019, time=2019-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369648, encodeId=952136964833, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/12/05/12a5266c80310ee47ca553700511f53c.jpg, createdBy=b5512215816, createdName=永远不放弃, createdTime=Sun Jul 14 11:16:31 CST 2019, time=2019-07-14, status=1, ipAttribution=)]
    2019-07-14 永远不放弃

    学习

    0

相关资讯

III期临床试验显示:诺华的CGRP抑制剂Aimovig治疗偏头痛展现出长期疗效

诺华的CGRP抑制剂Aimovig(erenumab-aooe)可将每月偏头痛天数减少一半左右。

JAMA Neurol:舒马替坦治疗偏头痛机制研究

研究认为,舒马替坦治疗偏头痛确实是通过与中枢5-HT1B受体结合产生的,偏头痛发作与内源性5-羟色胺增加有关

NEJM:口服降钙素基因相关肽受体拮抗剂Rimegepant治疗偏头痛

由此可见,相比于安慰剂,使用口服降钙素基因相关肽受体拮抗剂Rimegepant治疗偏头痛发作导致更高比例的患者没有疼痛和更麻烦的症状。

2019年美国神经病学学会年会:Teva将公布Fremanezumab的长期有效性和安全性数据

Teva制药公司近日宣布,将在第71届美国神经病学学会(AAN)年会上公布Fremanezumab的有效性和安全性的长期分析结果。为期52周的多中心、随机、双盲、平行组长期延伸研究证明,Fremanezumab治疗成人偏头痛能够预防药物反应不足并提高患者的生活质量。

Neurology:Erenumab治疗偏头痛效果显著

研究认为,Erenumab减少了慢性偏头痛患者的偏头痛频率和急性偏头痛的药物治疗天数,提高了生活质量

欧洲批准Teva的CGRP单抗Ajovy用于治疗偏头痛

Teva的偏头痛药物Ajovy(fremanezumab)已获得欧盟委员会批准,用于预防每月至少有4个偏头痛日的成人偏头痛患者。

Baidu
map
Baidu
map
Baidu
map